VR Logo

ADC Therapeutics SA (ADCT) download report


Healthcare | Biotechnology & Pharma Research

ADC Therapeutics SA (ADCT) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.

IPO Date: 16-Mar-1979

Pres & CEO: Dr. Ameet Mallik

Vice Chairman, Exec. VP & Gen. Counsel: Mr. Michael Forer L.L.B.

Listing: NYSE: ADCT

Country: Switzerland

Headquarters: Epalinges,

Website: https://www.adctherapeutics.com

Key Facts

Market cap: $594.51 Mln

Revenue (TTM): $80.42 Mln

Earnings (TTM): $-195.16 Mln

Cash: $430.87 Mln

Total Debt: $0.00 Mln

Insider's Holding: 52.35%

Liquidity: Low

52 Week range: $5.52 - 32.00

Shares outstanding: 76,810,496

5 Years Aggregate:

  • CFO: $-720.00 Mln
  • EBITDA: $-794.51 Mln
  • Net Profit: $-805.76 Mln

Stock Performance

Time Period ADC Therapeutics SA (ADCT) S&P BSE Sensex* S&P Small-Cap 600*
YTD-61.44-8.99-19.22
1 month5.41-3.40-9.34
3 months-45.41-8.50-14.58
1 Year-68.280.89-17.64
3 Years--10.415.91
5 Years--11.435.64
10 Years--11.7710.10
As on 29-Jun-2022 *As on 30-Jun-2022
Year ADC Therapeutics SA (ADCT) S&P Small-Cap 600 S&P BSE Sensex
2021-36.8925.2721.99